Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ACADIA PHARMACEUTICALS INC (ACAD)
|
Add to portfolio |
|
|
|
| Price: |
$24.39
| | Metrics |
| OS: |
162.6
|
M
| |
|
|
| Market cap: |
$3.97
|
B
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$3.97
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 484.1 | 441.8 | 339.1 | 223.8 | 124.9 | 17.3 | 0.1 | 0.1 |
| Revenue growth | 9.6% | 30.3% | 51.5% | 79.2% | 620.7% | 28311.5% | -49.2% | -89.5% |
| Cost of goods sold | 10.8 | 10.2 | 11.3 | 12.4 | 9.1 | 4.4 | 2.5 | 0.0 |
| Gross profit | 473.3 | 431.5 | 327.7 | 211.4 | 115.8 | 12.9 | -2.4 | 0.1 |
| Gross margin | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 74.6% | -3998.4% | 100.0% |
| Selling, general and administrative | 643.7 | 44.3 | 574.3 | 265.8 | 255.1 | 186.5 | 88.3 | 32.7 |
| Research and development | | | | 187.2 | 149.2 | 99.3 | 73.9 | 60.6 |
| EBITA | -169.3 | -240.8 | -245.1 | -246.0 | -290.9 | -271.8 | -164.6 | -93.2 |
| EBITA margin | -35.0% | -54.5% | -72.3% | -109.9% | -232.9% | -1568.5% | -269855.7% | -77691.7% |
| Amortization of intangibles | 1.1 | 1.5 | 1.5 | 1.5 | 1.5 | 1.0 | | |
| EBIT | -170.4 | -242.3 | -246.5 | -247.4 | -292.4 | -272.8 | -164.6 | -93.2 |
| EBIT margin | -35.2% | -54.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% |
| Pre-tax income | -167.5 | -281.0 | -234.4 | -243.9 | -288.3 | -270.1 | -164.1 | -92.5 |
| Income taxes | 0.4 | 0.6 | 0.9 | 1.3 | 1.1 | 1.3 | 0.3 | 0.0 |
| Tax rate | | | | | | | | 0.0% |
| Net income | -167.9 | -281.6 | -235.3 | -245.2 | -289.4 | -271.4 | -164.4 | -92.5 |
| Net margin | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% |
| |
| Diluted EPS | ($1.05) | ($1.79) | ($1.60) | ($1.94) | ($2.36) | ($2.34) | ($1.63) | ($0.95) |
| Shares outstanding (diluted) | 160.5 | 157.3 | 147.2 | 126.6 | 122.6 | 115.9 | 100.6 | 97.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|